Company Profile

Company Overview

Yumanity Therapeutics is transforming the discovery of new targets and therapeutics for neurodegenerative diseases caused by protein misfolding. Despite the chronic suffering of an estimated 50 million people worldwide from diseases affecting the brain and central nervous system, there are no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address illnesses such as Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease (AD). The company’s approach concentrates on identifying targets and therapeutics that correct cellular pathologies and the altered biology or phenotypes driven by misfolded proteins, which are known risk factors and drivers of these diseases.